ONCY Share Price Performance
US$1.24
0.00 (0.00%)
Price US$1.24
Share PriceUS$1.24
Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?
Sep 03
Oncolytics Biotech Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
ONCY Community Narratives
There are no narratives available yet.
Oncolytics Biotech Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.30
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Oncolytics Biotech Inc. Competitors
Snowflake Analysis
About ONCY
- Founded
- 1998
- Employees
- 28
- CEO
- WebsiteView website
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 10.0%
- 1 Year: 21.2%
- Year to Date: 19.9%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. More promisingly, the market is up 21% over the past year. Earnings are forecast to grow by 12% annually. Market details ›